(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of 316.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.41%.
Compass Therapeutics's revenue in 2024 is $850,000.On average, 3 Wall Street analysts forecast CMPX's revenue for 2024 to be $119,152,222, with the lowest CMPX revenue forecast at $116,950,795, and the highest CMPX revenue forecast at $123,830,254. On average, 2 Wall Street analysts forecast CMPX's revenue for 2025 to be $2,566,038,039, with the lowest CMPX revenue forecast at $1,692,346,803, and the highest CMPX revenue forecast at $3,439,729,275.
In 2026, CMPX is forecast to generate $8,667,842,595 in revenue, with the lowest revenue forecast at $1,795,538,682 and the highest revenue forecast at $20,594,347,115.